

06 August 2025

## **Urothelial Cancer Treatment**

### **Question One**

**How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:**

**Atezolizumab (Tecentriq): <5**

**Avelumab (Bavencio): <5**

**Carboplatin single agent or in any other combination Carbo/Etop: <5**

**Carboplatin with Gemcitabine: <5**

**Carboplatin with Gemcitabine + Avelumab (Bavencio): 0**

**Carboplatin with Paclitaxel: 0**

**Cisplatin single agent or in any other combination: 0**

**Cisplatin with Gemcitabine: <5**

**Cisplatin with Gemcitabine + Nivolumab (Opdivo): 0**

**Cisplatin with Gemcitabine + Avelumab (Bavencio): 0**

**Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda): 0**

**Nivolumab (Opdivo): 0**

**Pembrolizumab (Keytruda): 0**

**Other active systemic anti-cancer therapy: 0**

**Palliative care only: not available.**

**Erdafitinib: 0**

We are not able to provide the information requested. Due to low numbers of <5 would reduce numbers to discoverable limits, we consider that individuals could be identified and disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have

**06 August 2025**

concluded that this information is exempt from disclosure under FOI Act Section 40(2) Personal Information relating to a third party, of the FOI Act.

**Question Two**

**Does your trust participate in any ongoing clinical trials for the treatment of Urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?**

I can confirm that there are no clinical trials specific to Urothelial cancer open at this time.